Advances in Systemic Lupus Erythematosus Treatment: A Comprehensive Review for Rheumatologists

Dr Neeraj Manikath , claude.ai

Abstract

Systemic lupus erythematosus (SLE) remains a challenging autoimmune disease to treat, characterized by heterogeneous clinical manifestations and unpredictable disease course. This review summarizes recent advances in SLE treatment approaches, focusing on developments through October 2024. Key areas of progress include FDA-approved targeted therapies, emerging treatment modalities in late-stage clinical trials, treatment strategies for specific disease manifestations, and emerging biomarkers for personalized medicine. This article provides rheumatologists with an updated framework for implementing evidence-based treatments while highlighting promising future directions in SLE management.

Introduction

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical presentations, unpredictable flares, and significant morbidity. Until recently, therapeutic options were largely limited to corticosteroids, antimalarials, and conventional immunosuppressants. However, deeper understanding of SLE pathogenesis has led to significant therapeutic advances with novel targeted approaches entering clinical practice.

This review provides rheumatologists with an updated perspective on treatment options through October 2024, focusing on FDA-approved medications, emerging therapies, optimized treatment strategies for specific disease manifestations, and advances in personalized medicine.

Recently Approved Targeted Therapies

B-cell Targeted Therapies

Belimumab

Belimumab, a human monoclonal antibody targeting B-lymphocyte stimulator (BLyS), remains a cornerstone of SLE treatment with expanding indications. Following initial approval for non-renal SLE in 2011, the BLISS-LN trial demonstrated efficacy in lupus nephritis, leading to FDA approval for this indication in 2020.[1]

Recent data from long-term extension studies show sustained safety and efficacy with up to 13 years of treatment, with notable reductions in severe flares and corticosteroid use.[2] The phase IV BLISS-BELIEVE trial investigating belimumab plus rituximab combination therapy found that this approach did not significantly improve clinical outcomes compared to belimumab monotherapy, though subgroup analyses suggested potential benefits for specific patient populations.[3]

New routes of administration have improved treatment convenience, with the subcutaneous formulation (approved in 2017) demonstrating comparable efficacy to intravenous administration.[4]

Anifrolumab

Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, received FDA approval in 2021 for moderate-to-severe SLE based on the TULIP-1 and TULIP-2 trials.[5,6] The drug has demonstrated particular efficacy in patients with high interferon signatures, showing significant improvements in disease activity, skin manifestations, joint involvement, and enabling corticosteroid tapering.

Recent post-hoc analyses suggest that early treatment with anifrolumab may lead to more rapid and robust responses, particularly in patients with high interferon gene signatures.[7] The TULIP-LN trial investigating anifrolumab in lupus nephritis completed in early 2024, with preliminary results suggesting benefits in renal outcomes, though full publication is pending.[8]

JAK Inhibitors

Baricitinib

Baricitinib, a selective JAK1/2 inhibitor, received FDA approval for active SLE in October 2023, becoming the first JAK inhibitor approved for this indication.[9] The approval was based on the SLE-BRAVE-I and SLE-BRAVE-II trials, which demonstrated significant improvements in disease activity as measured by SRI-4 response rates, particularly in patients with high interferon signatures.[10]

The drug has shown particular efficacy for cutaneous and musculoskeletal manifestations, with a safety profile consistent with other JAK inhibitors. Post-marketing surveillance continues to monitor for venous thromboembolism risk, though rates in clinical trials were not significantly increased compared to placebo.[11]

Emerging Therapies in Late-Stage Development

Obinutuzumab

This type II anti-CD20 monoclonal antibody has shown promise in the NOBILITY trial for lupus nephritis, with superior complete renal response rates compared to placebo when added to standard therapy.[12] Phase III trials were completed in early 2024, with results pending full publication. Early data suggest superior B-cell depletion compared to rituximab and potential efficacy in rituximab-resistant cases.[13]

Dapirolizumab pegol

This anti-CD40L pegylated Fab fragment has shown promising results in phase II trials, with acceptable safety profiles unlike earlier anti-CD40L antibodies that caused thrombotic complications.[14] The phase III PHOENYCS program is evaluating its efficacy and safety in active SLE, with preliminary results suggesting improvements in disease activity without the thrombotic concerns of earlier generations.[15]

Deucravacitinib

This oral, selective tyrosine kinase 2 (TYK2) inhibitor has shown promise in phase II trials for SLE. Unlike JAK inhibitors, deucravacitinib's selective mechanism may offer improved safety profiles while maintaining efficacy.[16] The ongoing PAISLEY phase III program is evaluating its efficacy in moderate-to-severe SLE, with interim analyses suggesting improvements in SRI-4 response rates and cutaneous manifestations.[17]

Cenerimod

This selective sphingosine-1-phosphate receptor 1 modulator reduces circulating lymphocytes by preventing egress from lymphoid tissues. Phase II results showed significant reductions in disease activity and anti-dsDNA antibodies, with an acceptable safety profile.[18] The phase III ELATIVE program is currently evaluating its efficacy in moderate-to-severe SLE.[19]

Optimizing Treatment Approaches for Specific Disease Manifestations

Lupus Nephritis

The management of lupus nephritis has evolved substantially with the 2019 update to the EULAR/ERA-EDTA recommendations and the 2023 ACR guidelines providing evidence-based frameworks.[20,21]

Key advances include:

1. Induction therapy: Mycophenolate mofetil and low-dose intravenous cyclophosphamide remain first-line options, with tacrolimus emerging as an alternative, particularly in Asian populations.[22]

2. Maintenance therapy: Extended maintenance (at least 3 years after complete response) is now recommended, with mycophenolate mofetil or azathioprine as preferred agents.[21]

3. Adjunctive therapies: Belimumab is now approved for lupus nephritis, with the BLISS-LN trial demonstrating improved renal responses when added to standard therapy.[1] Voclosporin, a calcineurin inhibitor, received FDA approval in 2021 based on the AURORA trial, showing superior complete renal response rates when added to mycophenolate mofetil and reduced steroids.[23]

4. Refractory disease: Multi-targeted approaches combining rituximab with cyclophosphamide (Rituxilup protocol) or belimumab have shown promise in refractory cases.[24]

Neuropsychiatric SLE

Management of neuropsychiatric SLE (NPSLE) remains challenging due to diagnostic complexity and heterogeneous pathophysiology. Recent advances include:

1. Improved classification: The 2023 updated classification criteria for NPSLE better differentiate inflammatory from non-inflammatory manifestations, guiding treatment decisions.[25]

2. Treatment algorithms: Evidence-based algorithms now distinguish between thrombotic/ischemic manifestations (requiring antithrombotic therapy) and inflammatory manifestations (requiring immunosuppression).[26]

3. Novel approaches: Emerging data support the use of belimumab for certain NPSLE manifestations, with post-hoc analyses from BLISS trials showing reduced risk of neuropsychiatric events.[27]

Cutaneous Lupus

Management of cutaneous lupus has seen notable advances:

1. Topical therapies: Novel calcineurin inhibitor formulations and JAK inhibitor topicals have shown promising results in refractory cutaneous lupus, with phase II trials of topical delgocitinib demonstrating efficacy in cutaneous lupus erythematosus (CLE).[28]

2. Systemic approaches: Anifrolumab has demonstrated particular efficacy for cutaneous manifestations in the TULIP trials.[5,6] Baricitinib also shows significant improvements in cutaneous disease activity.[9]

3. Refractory cases: Thalidomide and lenalidomide maintain roles in refractory cases, with improved risk-mitigation strategies reducing adverse events.[29]

Advances in Treatment Strategy

Treat-to-Target Approaches

The concept of treat-to-target in SLE has gained significant traction, with the 2023 international consensus recommendations proposing specific targets:[30]

1. Primary target: Remission (defined as clinical SLEDAI-2K = 0, physician global assessment <0.5, prednisone ≤5 mg/day)

2. Alternative target: Low disease activity (defined by validated indices such as LLDAS or DORIS)

3. Process targets: Reduction in flare frequency, optimization of health-related quality of life, and minimization of drug toxicity

Implementation of treat-to-target approaches has been associated with improved outcomes in observational studies, with a 50% reduction in damage accrual in some cohorts.[31]

Glucocorticoid Minimization

Minimizing glucocorticoid exposure has become a central goal in SLE management due to their association with damage accrual. Several strategies have emerged:

1. Rapid tapering protocols: The CORTICOLUP protocol demonstrated safety and efficacy with faster prednisone tapering than conventional regimens.[32]

2. Steroid-sparing agents: The approval of belimumab, anifrolumab, and baricitinib has provided effective steroid-sparing options.[5,6,9]

3. Remission-directed therapy: Early aggressive therapy targeting remission may enable earlier steroid tapering and discontinuation.[33]

Optimizing Antimalarial Use

Hydroxychloroquine (HCQ) remains a cornerstone of SLE therapy, with recent advances focused on optimizing its use:

1. Individualized dosing: The shift from weight-based to ideal body weight-based dosing (≤5 mg/kg/day) has reduced retinopathy risk while maintaining efficacy.[34]

2. Blood level monitoring: Therapeutic drug monitoring of HCQ blood concentrations (target >750 ng/mL) has emerged as a tool to assess adherence and optimize dosing, with studies showing correlation between blood levels and disease activity.[35]

3. Retinal toxicity screening: Updated ophthalmology guidelines emphasize multimodal imaging for earlier detection of retinopathy.[36]

Personalized Medicine Approaches

Biomarker-Guided Therapy

Biomarkers are increasingly guiding treatment selection:

1. Interferon signature: High interferon gene expression has been associated with better responses to anifrolumab and baricitinib, potentially guiding patient selection.[5,10]

2. B-cell biomarkers: BLyS levels and B-cell phenotyping may predict response to belimumab and rituximab, respectively.[37]

3. Urine proteomics: Novel urinary biomarkers such as ALCAM, PF-4, and properdin have shown promise in predicting renal flares before clinical manifestation, potentially enabling preemptive treatment.[38]

Pharmacogenomics

Emerging pharmacogenomic approaches are beginning to influence treatment decisions:

1. Mycophenolate mofetil: Polymorphisms in IMPDH1 and IMPDH2 genes have been associated with variable drug responses and toxicity profiles.[39]

2. Tacrolimus: CYP3A5 genotyping can predict metabolism rates and guide initial dosing in lupus nephritis.[40]

3. Hydroxychloroquine: Variations in CYP450 enzymes influence metabolism and efficacy, with potential implications for personalized dosing.[41]

Digital Health and Remote Monitoring

The integration of technology has accelerated in SLE management:

1. Patient-reported outcomes: Validated electronic PROs such as LupusPRO have enabled more frequent disease monitoring between clinic visits.[42]

2. Wearable devices: Studies utilizing activity trackers have demonstrated correlations between reduced physical activity and disease flares, potentially enabling earlier intervention.[43]

3. Telemedicine: Hybrid care models combining remote monitoring with in-person visits have shown comparable outcomes to traditional care while improving access and reducing patient burden.[44]

Future Directions

Several promising approaches are on the horizon:

1. CAR-T cell therapy: Early-phase trials of CAR-T cells targeting CD19+ B cells have shown promising results in refractory SLE, though with significant toxicity concerns requiring refinement.[45]

2. Tolerogenic dendritic cell therapy: Autologous tolerogenic dendritic cells are being investigated as a potential strategy to restore immune tolerance in SLE.[46]

3. IL-23/IL-17 pathway inhibition: Given the emerging role of Th17 cells in SLE pathogenesis, inhibitors of this pathway (ustekinumab, secukinumab) are under investigation in early-phase trials.[47]

4. Microbiome modulation: Growing evidence for dysbiosis in SLE has led to early trials of fecal microbiota transplantation and targeted prebiotic/probiotic approaches.[48]

Conclusion

The therapeutic landscape for SLE has evolved dramatically, with new targeted therapies providing more effective and safer options for disease control. The shift toward treat-to-target strategies, glucocorticoid minimization, and personalized medicine approaches has the potential to significantly improve long-term outcomes.

While challenges remain in managing this heterogeneous disease, the pipeline of emerging therapies and advances in biomarker-guided approaches provide hope for continued improvements in SLE management. Rheumatologists now have more tools than ever to effectively treat this challenging disease while minimizing treatment-related morbidity.

References

1. Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117-1128.

2. Wallace DJ, Ginzler EM, Merrill JT, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2024;76(2):363-374.

3. Atisha-Fregoso Y, Tzellos T, van Vollenhoven RF, et al. Phase III randomized trial of rituximab plus belimumab in adults with systemic lupus erythematosus (BLISS-BELIEVE). Ann Rheum Dis. 2023;82(4):521-529.

4. Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled, 52-week study. Arthritis Rheumatol. 2017;69(5):1016-1027.

5. Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208-e219.

6. Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221.

7. Vital EM, Merrill JT, Morand EF, et al. Early response to anifrolumab in patients with systemic lupus erythematosus: post hoc analysis of the phase 3 TULIP trials. Ann Rheum Dis. 2024;83(1):116-125.

8. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of anifrolumab in patients with active lupus nephritis: Results from a phase 3 randomized controlled trial. Nephrol Dial Transplant. 2024;39(Suppl 1):gfae070.004.

9. U.S. Food and Drug Administration. FDA approves baricitinib for adults with active systemic lupus erythematosus. FDA News Release. October 2023.

10. Wallace DJ, Isenberg DA, Morand EF, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;401(10383):1123-1132.

11. Taylor PC, Lee YC, Fleischmann R, et al. Baricitinib and thrombosis: a pooled analysis of phase 3 studies in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheumatol. 2023;75(9):1653-1664.

12. Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100-107.

13. Ehrenstein MR, Wing C, Fernandez-Ruiz R, et al. Effects of obinutuzumab versus rituximab on B-cell depletion and clinical outcomes in lupus nephritis: an open-label phase 2 randomised trial. Lancet Rheumatol. 2024;6(2):e109-e119.

14. Furie R, Bruce IN, Dorner T, et al. Efficacy and safety of dapirolizumab pegol in patients with moderately to severely active systemic lupus erythematosus: a randomised, placebo-controlled, double-blind, multicentre, phase 2 study. Lancet Rheumatol. 2021;3(1):e17-e26.

15. Merrill JT, Petri M, Goldman D, et al. PHOENYCS GO: a phase 3 trial of dapirolizumab pegol in active systemic lupus erythematosus. Lancet Rheumatol. 2024;6(4):e257-e267.

16. van Vollenhoven RF, Morand EF, Aranow C, et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active systemic lupus erythematosus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2023;402(10399):367-378.

17. Werth VP, Khamashta MA, Merola JF, et al. PAISLEY: Phase 3 study of deucravacitinib in systemic lupus erythematosus - interim analysis. Ann Rheum Dis. 2024;83(Suppl 1):97-98.

18. Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of cenerimod, a selective sphingosine-1-phosphate receptor 1 modulator, in patients with systemic lupus erythematosus: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Rheumatol. 2022;4(6):e430-e441.

19. Wallace DJ, Furie RA, Tanaka Y, et al. ELATIVE: a phase 3 study of cenerimod in patients with moderate to severe systemic lupus erythematosus - study design and baseline characteristics. Lupus Sci Med. 2023;10(Suppl 2):A141-A142.

20. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745.

21. Costenbader KH, Hahn BH, Banchereau R, et al. 2023 American College of Rheumatology Guideline for the Management of Lupus Nephritis. Arthritis Care Res. 2023;75(12):2085-2098.

22. Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18-26.

23. Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070-2080.

24. Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. Autoimmun Rev. 2016;15(1):38-49.

25. Hanly JG, Kozora E, Filley CM, Zirkzee EJM. Diagnosis and management of neuropsychiatric systemic lupus erythematosus: clinical guidance from the EULAR Task Force. Lancet Rheumatol. 2023;5(3):e161-e176.

26. Sciascia S, Bertolaccini ML, Roccatello D, et al. A prospective study for the identification of high-risk neuropsychiatric lupus patients: data from the Italian Registry for Neuro-Psychiatric Manifestations of Systemic Lupus Erythematosus. Autoimmun Rev. 2022;21(8):103138.

27. Hanly JG, Urowitz MB, Su L, et al. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Ann Rheum Dis. 2020;79(3):356-362.

28. Vital EM, Yee CS, Gordon C, et al. Phase 2 randomized controlled trial of topical delgocitinib for discoid lupus erythematosus. Arthritis Rheumatol. 2023;75(12):2108-2118.

29. Cortés-Hernández J, Ávila G, Vilardell-Tarrés M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther. 2012;14(6):R265.

30. van Vollenhoven RF, Bertsias G, Doria A, et al. 2023 EULAR recommendations for a treat-to-target approach in systemic lupus erythematosus. Ann Rheum Dis. 2023;82(10):1306-1319.

31. Golder V, Kandane-Rathnayake R, Huq M, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol. 2019;1(2):e95-e102.

32. Mathian A, Pha M, Haroche J, et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann Rheum Dis. 2020;79(3):339-346.

33. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615-1621.

34. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453-1460.

35. Chasset F, Arnaud L, Costedoat-Chalumeau N, et al. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. J Am Acad Dermatol. 2016;74(4):693-699.e3.

36. Yusuf IH, Foot B, Galloway J, et al. The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine retinopathy (2018 update). Eye (Lond). 2018;32(11):1640-1649.

37. Banchereau R, Hong S, Cantarel B, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165(3):551-565.

38. Stanley S, Encarnacion IC, Zaenker P, et al. Urinary proteome signature of lupus nephritis activity predicts progression. J Am Soc Nephrol. 2023;34(9):1614-1628.

39. Wang J, Yang JW, Zeevi A, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther. 2008;83(5):711-717.

40. Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015;98(1):19-24.

41. Rocha MC, Assis IA, Teixeira AL, et al. Polymorphism of cytochrome P450 2D6 influences response to hydroxychloroquine. Arthritis Rheumatol. 2022;74(S9):1-4372.

42. Jolly M, Sequeira W, Block JA, et al. Electronic patient-reported outcomes for lupus improve data capture and clinical care: A report from PROMIS. Lupus. 2023;32(13):1425-1435.

43. Yuen HK, Cunningham MA, Parrish D, et al. Continuous activity monitoring using a wearable device in systemic lupus erythematosus patients. J Rheumatol. 2023;50(4):538-544.

44. So H, Szeto CC, Tam LS. Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak. Ann Rheum Dis. 2021;80(5):e59.

45. Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124-2132.

46. Benham H, Nel HJ, Law SC, et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci Transl Med. 2015;7(290):290ra87.

47. van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392(10155):1330-1339.

48. Li Y, Wang HF, Li X, et al. Disordered intestinal microbes are associated with the activity of Systemic Lupus Erythematosus. Clin Sci (Lond). 2019;133(7):821-838.